Drug intelligence / Profile preview

YIV-111

Development stage: Preclinical
Lead developer: Yiviva

Overview

YIV-111 is a botanical drug candidate in preclinical development by Yiviva for the treatment of respiratory diseases. [1] Inspired by traditional Chinese medicine, it is a systems biology-based medicine that acts on multiple targets. [1] Its proposed mechanisms include reducing inflammation, fibrosis, oxidative stress, and both bacterial and viral virulence. [1, 2] Yiviva is exploring YIV-111 for its potential to prevent or treat the progression of lung diseases, such as chronic inflammation, pulmonary fibrosis, and cancer pneumonia. [1, 2]

Beyond the preview

Go deeper on YIV-111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YIV-111.

Explore the full profile